According to FutureWise analysis, the market for actinic keratosis treatment is projected to expand at a CAGR of 4.3% from 2023-2031.
Actinic keratosis is caused due to overexposure to the harmful UV rays. Face and back of the palm are the primary areas where actinic keratosis is prominently observed. It can cause skin cancer if neglected for long. This is primarily observed in regions with a thin layer of ozone and these are the potential market regions for actinic keratosis treatment. Based on the type of treatment provided, the market is bifurcated into topical treatment, photodynamic therapy and procedural modality. Topical treatment is further segmented in to 5-fluorouracil cream, diclofenac gel, Imiquimod cream and Ingenol mebutane gel while procedural modality is sub-segmented into chemical peels and cryotherapy.
Bassed on the end user, the market is bifurcated into hospitals, private dermatology clinics, laser therapy centres, cancer treatment centres, spas, rejuvenation centre and home care. Homecare segment has good potential for market growth as there has been an increase in consumer awareness and the availability of various self-care affordable options thus targeting the emerging economic market space. By the type of disease, the market is segmented into clinical actinic keratosis and sub-clinical actinic keratosis. North America dominates this market and will continue to do the same during the forecast period. North America has a thin ozone layer exposing it to the harmful ultraviolet rays and as a result of this, the majority of actinic keratosis patients are from this region.
However, the European region is also making significant progress in this market and will achieve a high value of CAGR during the forecast period. The middle east African region account for the least market share owing to low per person income which makes the treatment inaccessible to the masses.